Astec Lifesciences share price today

Astec Lifesciences Ltd's share price was ₹567.40 at the close on 4 November 2026. It has been falling for 12 weeks. That is 17.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹543 and ₹838, and at that close it sat 8% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Astec Lifesciences Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.

Over the last 11 years the share price moved +188% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: profit fell in the September 2026 quarter and lowest operating margin in 9 quarters.

1. Profit fell in the September 2026 quarter

   Profit was ₹-37 crore, -54.2% on a year earlier (₹-24 crore), after 5 quarters of growth.

2. Lowest operating margin in 9 quarters

   Operating margin was -27% in the September 2026 quarter, against -9% a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Astec Lifesciences reported revenue of ₹72.0 crore, down 2.7% from ₹74.0 crore a year earlier, and a loss of ₹37.0 crore.

Astec Lifesciences results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Astec Lifesciences closed at ₹567.40 on 4 November 2026, down 10.3% from ₹632.75 a year earlier (7 November 2025) and down 56.2% over five years. Its highest weekly close since March 2016 was ₹2,157.55 on 4 November 2022.

Astec Lifesciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Astec Lifesciences closed at ₹567.40, up 3.8% on the week and down 19.9% on the month. Results for July to September 2026: Revenue down 2.7% on a year earlier.

Astec Lifesciences paid no dividend in the 12 months to 5 November 2026. The last was a dividend of ₹1.50 a share, ex-date 21 July 2023.

Astec Lifesciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Not in its latest year. Astec Lifesciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 9 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

Astec Lifesciences is not on any of our India lists this week.

Astec Lifesciences Ltd posted a net loss of ₹37.0 Cr in the Sep 2026 quarter. The full FY26 year was a loss of ₹81.0 Cr. That loss is 51.4% of the quarter's revenue. The same quarter a year earlier lost ₹24.0 Cr. 12 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Astec Lifesciences Ltd reported ₹72.0 Cr of revenue in the Sep 2026 quarter, −2.7% on the same quarter a year earlier. Over 10 years it has grown 6.8% a year on average. The last full year, FY26, came in at ₹448 Cr. The last four reported quarters add to ₹440 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹448 Cr, +17.6% on the year before.

Recent pace: the last four quarters grew +13.8% on average, against 6.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +16.1%, against +8.6% a year over the last 8 quarters (accelerating).

Astec Lifesciences Ltd's operating margin was −27.0% in the Sep 2026 quarter, 18.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between −17.0% and 23.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −18.4 percentage points on the year while gross margin changed −16.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 50% of Astec Lifesciences Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹81.0 Cr of cash, against −₹81.0 Cr of profit. After ₹4.0 Cr of spending on assets, free cash was −₹85.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 50% of profit came in as cash: the cash cycle got 163 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 163 days longer. The next section looks at where the cash is stuck.

Astec Lifesciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 263 days in FY26, up from 100 days in FY21. It spent ₹159 Cr on assets over the last 3 years. Customers take 202 days to pay, and stock sits for 169 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹448 Cr, each day of that cycle ties up about ₹1.2 Cr, so roughly ₹323 Cr is tied up in the business at any time.

FY26: customers took 202 days to pay and stock sat for 169 days, about 5.6 months of sales sitting as stock, for a full cycle of 263 days, longer than FY21's 100.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 169 days. Customers pay about 202 days after that. Suppliers are paid at 107 days. Together that makes the 263-day cycle.

Spending on assets: ₹159 Cr over the last 3 years, against ₹125 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹20.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Astec Lifesciences Ltd's P/E is 110.6×, near the high end of its own history: higher than 94% of past readings. Its usual P/E (the middle reading) is 46.4×, over 7.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.